Mapping the nigrostriatal pathway in early Parkinson's
Our new Neurobiology of Disease paper mapping nigrostriatal degeneration with diffusion MRI.
Read more →We are a multidisciplinary research group that combines advanced neuroimaging and therapeutic ultrasound to develop diagnostic biomarkers and pioneering non-invasive therapeutic approaches for neurodegenerative disease.
Bringing together engineers, physicists and computer scientists, we develop cutting-edge technological solutions to advance neuroengineering and applied neuroscience.
Reaching deep brain structures without a single incision.
AI and large-scale data power our biomarkers and predictive models.
A direct link between scientific discovery and clinical reality.
Our work spans the full arc of non-invasive neurotechnology.
FDOPA and FDG PET biomarkers of dopaminergic function.
Diffusion and quantitative MRI of brain microstructure.
ML and disease-progression models for Parkinson's disease.
Precise, incision-free lesioning of deep brain targets.
Ultrasound-enabled drug and gene delivery across the BBB.
Transcranial stimulation to map circuits and find targets.
A data-driven decision-support platform for MR-guided high-intensity focused ultrasound.
Pooling real-world data from nine centers and applying machine learning to optimize every stage of MR-guided HIFU.
Our new Neurobiology of Disease paper mapping nigrostriatal degeneration with diffusion MRI.
Read more →
The detailed timeline and milestones for our BBB-opening project.
Read more →
A week in the French Alps with leaders in therapeutic ultrasound.
Read more →
A successful doctoral defence on nigrostriatal degeneration.
Read more →We partner with academia, clinicians and industry pioneers.
Start a conversation →